However, keeping in mind that clinically highly valuable patient collectives [18–22] are based on serum samples, we wondered if innovative Intplex PCR, first published by Thierry et al. [6], could be a reliable technology for sensitive analysis of oncological KRAS mutations in CRC patients’ serum samples as well. Here, KRAS is linked to colorectal carcinoma.